Safety and effectiveness of omalizumab for chronic spontaneous urticaria inadequately controlled with H1 antihistamines in Chinese adolescents: a real-world, prospective, multicenter study.

Yu Wang¹, Chengzhi Lv², Bin Yang³, Zigang Xu⁴, Lin Ma⁴, Lixiong Gu⁵, Zhiming Li⁶, Niu Xiang⁷, Xiaoyong Man⁸, Juan Su⁹, Liming Wu¹⁰, Min Shu¹¹, Sirao Wang¹¹, Yujia Song¹¹, Yumeng Ren¹², Yuling Shi¹³

¹Shanghai Skin Disease Hospital, Shanghai, China.

²Dalian Dermatology Hospital, Dalian, China.

³Dermatology Hospital of Southern Medical University, Guangzhou, China.

⁴Beijing Children's Hospital, Capital Medical University, Beijing, China.

⁵Department of Hematology, Affiliated Hospital of Nantong University, Nantong, China.

⁶The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

⁷The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.

⁸The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.

⁹Xiangya Hospital of Central South University, Changsha, China.

¹⁰Hangzhou First People's Hospital, Hangzhou, China.

¹¹China Novartis Institutes for Biomedical Research, Shanghai, China.

¹²IQVIA, Real World Evidence and Clinical Technology Solutions, San Francisco, CA, USA.

¹³Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.

PubMed DOI

Abstract

OBJECTIVE: Chronic spontaneous urticaria (CSU) is a burdensome skin disorder that may remain inadequately controlled with standard H1 antihistamines (H1 AHs). Evidence on adolescents with CSU is limited. This 16-week study evaluated the safety and effectiveness of omalizumab in Chinese adolescents (≥12 to <18 years) with CSU who remained symptomatic despite H1 AH treatment (treatment period: 12 we…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.